Memantine

Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.

Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.

Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.

Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.

Muna da masana'antu masu inganci da yawa tare da haɗin gwiwa mai zurfi, wanda zai iya ba ku samfuran inganci da farashin gasa. Kuma muna iya ba da rangwamen kuɗi don sayayya mai yawa. Kuma muna ba da haɗin kai tare da ƙwararrun kamfanoni masu jigilar kaya, za su iya isar da samfuran cikin aminci da kwanciyar hankali ga hannunku. Lokacin bayarwa shine kimanin kwanaki 3-20 bayan tabbatar da biyan kuɗi.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other. 

1. Shin ku masana'anta ne ko kamfani na kasuwanci?
Mu kamfani ne mai haɗa masana'antu da kasuwanci, samar da sabis na tsayawa ɗaya. Ana iya karɓar OEM.

2. Kuna samar da samfurori? Yana da kyauta ko kari?
Samfuran kyauta. Ana buƙatar biyan kuɗin jigilar samfurin ta gefen ku.

3. Kuna da wasu takaddun shaida masu alaƙa da kula da inganci?
ISO 9001: 2008 takardar shaida don tabbatar da inganci.

4. Menene zan bayar don samun zance?
Pls sanar da mu nau'in samfurin wanda kuke buƙata, adadin oda, adireshi da takamaiman buƙatu. Za a yi zance don bayanin ku cikin lokaci.

5. Wane irin hanyar biyan kuɗi kuka fi so? Wane irin sharuɗɗan ne ake karɓa?
Sharuɗɗan Isar da Karɓa: FOB, CFR, CIF, EXW;
Kudin Biyan Da Aka Karɓa: USD;
Nau'in Biyan Da Aka Karɓa: T/T, Western Union; Paypal, Tabbacin Kasuwanci.
Harshe Ana Magana: Turanci.